Jefferies Financial Group Inc. Reduces Stock Position in Indivior PLC $INDV

Jefferies Financial Group Inc. cut its holdings in shares of Indivior PLC (NASDAQ:INDV) by 31.2% during the 4th quarter, Holdings Channel.com reports. The firm owned 486,826 shares of the company’s stock after selling 220,375 shares during the quarter. Jefferies Financial Group Inc.’s holdings in Indivior were worth $17,467,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Quarry LP purchased a new stake in Indivior during the 3rd quarter worth approximately $26,000. Raymond James Financial Inc. purchased a new stake in Indivior during the 2nd quarter worth approximately $26,000. Salomon & Ludwin LLC purchased a new stake in Indivior during the 4th quarter worth approximately $30,000. Harbor Capital Advisors Inc. increased its holdings in Indivior by 309.9% during the 4th quarter. Harbor Capital Advisors Inc. now owns 1,033 shares of the company’s stock worth $37,000 after purchasing an additional 781 shares during the last quarter. Finally, GAMMA Investing LLC increased its holdings in Indivior by 544.6% during the 4th quarter. GAMMA Investing LLC now owns 1,199 shares of the company’s stock worth $43,000 after purchasing an additional 1,013 shares during the last quarter. 60.33% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at Indivior

In other news, Director Stuart A. Kingsley purchased 940 shares of the stock in a transaction dated Friday, March 6th. The stock was acquired at an average cost of $31.86 per share, for a total transaction of $29,948.40. Following the acquisition, the director owned 5,582 shares of the company’s stock, valued at $177,842.52. The trade was a 20.25% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through this link. Company insiders own 0.74% of the company’s stock.

Indivior Stock Performance

Shares of NASDAQ INDV opened at $37.53 on Monday. Indivior PLC has a twelve month low of $11.08 and a twelve month high of $41.00. The company has a market capitalization of $4.58 billion, a price-to-earnings ratio of 19.25 and a beta of 0.90. The business has a 50 day simple moving average of $33.39 and a 200-day simple moving average of $33.74.

Indivior (NASDAQ:INDV) last issued its quarterly earnings results on Tuesday, March 31st. The company reported $0.96 earnings per share for the quarter. Indivior had a negative return on equity of 219.26% and a net margin of 19.44%.The business had revenue of $317.00 million during the quarter. As a group, equities analysts predict that Indivior PLC will post 3.35 earnings per share for the current year.

Analysts Set New Price Targets

Several equities research analysts have issued reports on INDV shares. Weiss Ratings downgraded Indivior from a “hold (c+)” rating to a “hold (c)” rating in a report on Wednesday, May 6th. Zacks Research upgraded Indivior from a “hold” rating to a “strong-buy” rating in a report on Monday, March 16th. One equities research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has assigned a Hold rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Buy” and an average price target of $39.33.

Indivior Profile

Indivior plc is a specialty pharmaceutical company dedicated to developing and delivering treatments for addiction and related mental health disorders. The company’s portfolio centers on therapies designed to support individuals dealing with opioid dependence, alcohol use disorder and other behavioral health challenges. Its lead products include Suboxone® (buprenorphine and naloxone) sublingual film and Sublocade® (extended-release buprenorphine) injection, both of which are approved in multiple markets to aid in opioid use disorder management.

Indivior was established in 2014 through a demerger from the pharmaceuticals division of Reckitt Benckiser Group plc, inheriting decades of research and commercial expertise in addiction medicine.